|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lam B, Lam WK, Lam CL, Ooi GC, Ho JC, Wong
MP and Tsang KW: Adenocarcinoma of the lung in Chinese patients: A
revisit and some perspectives from the literature. Postgrad Med J.
77:708–712. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu Y, Inoue M, Sobue T and Tsugane S:
Reproductive factors, hormone use and the risk of lung cancer among
middle-aged never-smoking Japanese women: A large-scale
population-based cohort study. Int J Cancer. 117:662–666. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chlebowski RT, Schwartz AG, Wakelee H,
Anderson GL, Stefanick ML, Manson JE, Rodabough RJ, Chien JW,
Wactawski-Wende J, Gass M, et al: Oestrogen plus progestin and lung
cancer in postmenopausal women (Womens Health Initiative trial): A
post-hoc analysis of a randomized controlled trial. Lancet.
374:1243–1251. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bouchardy C, Benhamou S, Schaffar R,
Verkooijen HM, Fioretta G, Schubert H, Vinh-Hung V, Soria JC,
Vlastos G and Rapiti E: Lung cancer mortality risk among breast
cancer patients treated with anti-estrogens. Cancer. 117:1288–1295.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Márquez-Garbán DC, Chen HW, Fishbein MC,
Goodglick L and Pietras RJ: Estrogen receptor signaling pathways in
human non-small cell lung cancer. Steroids. 72:135–143. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pietras RJ, Márquez DC, Chen HW, Tsai E,
Weinberg O and Fishbein M: Estrogen and growth factor receptor
interactions in human breast and non-small cell lung cancer cells.
Steroids. 70:372–381. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hershberger PA, Vasquez AC, Kanterewicz B,
Land S, Siegfried JM and Nichols M: Regulation of endogenous gene
expression in human non-small cell lung cancer cells by estrogen
receptor ligands. Cancer Res. 65:1598–1605. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Enmark E, Pelto-Huikko M, Grandien K,
Lagercrantz S, Lagercrantz J, Fried G, Nordenskjöld M and
Gustafsson JA: Human estrogen receptor beta-gene structure,
chromosomal localization, and expression pattern. J Clin Endocrinol
Metab. 82:4258–4265. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stabile LP, Davis AL, Gubish CT, Hopkins
TM, Luketich JD, Christie N, Finkelstein S and Siegfried JM: Human
non-small cell lung tumors and cells derived from normal lung
express both estrogen receptor alpha and beta and show biological
responses to estrogen. Cancer Res. 62:2141–2150. 2002.PubMed/NCBI
|
|
11
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han BH, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stabile LP and Siegfried JM: Estrogen
receptor pathways in lung cancer. Curr Oncol Rep. 6:259–267. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stabile LP, Lyker JS, Gubish CT, Zhang W,
Grandis JR and Siegfried JM: Combined targeting of the estrogen
receptor and the epidermal growth factor receptor in non-small cell
lung cancer shows enhanced antiproliferative effects. Cancer Res.
65:1459–1470. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Siegfried JM, Gubish CT, Rothstein ME,
Henry C and Stabile LP: Combining the multitargeted tyrosine kinase
inhibitor vandetanib with the antiestrogen fulvestrant enhances its
antitumor effect in non-small cell lung cancer. J Thorac Oncol.
7:485–495. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pietras RJ and Márquez-Garbán DC:
Membrane-associated estrogen receptor signaling pathways in human
cancers. Clin Cancer Res. 13:4672–4676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Detterbeck FC, Boffa DJ and Tanoue LT: The
new lung cancer staging system. Chest. 136:260–271. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bai H, Mao L, Wang HS, Zhao J, Yang L, An
TT, Wang X, Duan CJ, Wu NM, Guo ZQ, et al: Epidermal growth factor
receptor mutations in plasma DNA samples predict tumor response in
Chinese patients with stages IIIB to IV non-small-cell lung cancer.
J Clin Oncol. 27:2653–2659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang S, An T, Wang J, Zhao J, Wang Z, Zhuo
M, Bai H, Yang L, Zhang Y, Wang X, et al: Potential clinical
significance of a plasma-based KRAS mutation analysis in patients
with advanced non-small cell lung cancer. Clin Cancer Res.
16:1324–1330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jackman DM, Yeap BY, Sequist LV, Lindeman
N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS,
et al: Exon 19 deletion mutations of epidermal growth factor
receptor are associated with prolonged survival in non-small cell
lung cancer patients treated with gefitinib or erlotinib. Clin
Cancer Res. 12:3908–3914. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Sheng J, Kang S, Fang W, Yan Y,
Hu Z, Hong S, Wu X, Qin T, Liang W and Zhang L: Patients with exon
19 deletion were associated with longer progression-free survival
compared to those with L858R mutation after first-line EGFR-TKIs
for advanced non-small cell lung cancer: A meta-analysis. PLoS One.
9:e1071612014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sequist LV, Martins RG, Spigel D, Grunberg
SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky
A, et al: First-line gefitinib in patients with advanced
non-small-cell lung cancer harboring somatic EGFR mutations. J Clin
Oncol. 26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jala VR, Radde BN, Haribabu B and Klinge
CM: Enhanced expression of G-protein coupled estrogen receptor
(GPER/GPR30) in lung cancer. BMC Cancer. 12:6242012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tanaka K, Shimizu K, Kakegawa S, Ohtaki Y,
Nagashima T, Kaira K, Horiguchi J, Oyama T and Takeyoshi L:
Prognostic significance of aromatase and estrogen receptor beta
expression in EGFR wild-type lung adenocarcinoma. Am J Transl Res.
8:81–97. 2016.PubMed/NCBI
|
|
25
|
Gomez-Fernandez C, Mejias A, Walker G and
Nadji M: Immunohistochemical expression of estrogen receptor in
adenocarcinomas of the lungg: The antibody factor. Appl
Immunohistochem Mol Morphol. 18:137–141. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schwartz AG, Prysak GM, Murphy V, Lonardo
F, Pass H, Schwartz J and Brooks S: Nuclear estrogen receptor beta
in lung cancer: Expression and survival differences by sex. Clin
Cancer Res. 11:7280–7287. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Skov BG, Fischer BM and Pappot H:
Oestrogen receptor beta over expression in males with non-small
cell lung cancer is associated with better survival. Lung Cancer.
59:88–94. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stabile LP, Dacic S, Land SR, Lenzner DE,
Dhir R, Acquafondata M, Landreneau RJ, Grandis JR and Siegfried JM:
Combined analysis of estrogen receptor beta-1 and progesterone
receptor expression identifies lung cancer patients with poor
outcome. Clin Cancer Res. 17:154–164. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fasco MJ, Hurteau GJ and Spivack SD:
Gender-dependent expression of alpha and beta estrogen receptors in
human nontumor and tumor lung tissue. Mol Cell Endocrinol.
188:125–140. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Toh CK, Ahmad B, Soong R, Chuah KL, Tan
SH, Hee SW, Leong SS, Tan EH and Lim WT: Correlation between
epidermal growth factor receptor mutations and expression of female
hormone receptors in east-Asian lung adenocarcinomas. J Thorac
Oncol. 5:17–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun HB, Zheng Y, Ou W, Fang Q, Li P, Ye X,
Zhang BB, Yang H and Wang SY: Association between hormone receptor
expression and epidermal growth factor receptor mutation in
patients operated on for non-small cell lung cancer. Ann Thorac
Surg. 91:1562–1567. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen XQ, Zheng LX, Li ZY and Lin TY:
Clinicopathological significance of oestrogen receptor expression
in non-small cell lung cancer. J Int Med Res. 45:51–58. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nose N, Sugio K, Oyama T, Nozoe T, Uramoto
H, Iwata T, Onitsuka T and Yasumoto K: Association between estrogen
receptor-beta expression and epidermal growth factor receptor
mutation in the postoperative prognosis of adenocarcinoma of the
lung. J Clin Oncol. 27:411–417. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Raso MG, Behrens C, Herynk MH, Liu S,
Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, et al:
Immunohistochemical expression of estrogen and progesterone
receptors identifies a subset of NSCLCs and correlates with EGFR
mutation. Clin Cancer Res. 15:5359–5368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Deng F, Li M, Shan WL, Qian LT, Meng SP,
Zhang XL and Wang BL: Correlation between epidermal growth factor
receptor mutations and the expression of estrogen receptor-β in
advanced non-small cell lung cancer. Oncol Lett. 13:2359–2365.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Olivo-Marston SE, Mechanic LE, Mollerup S,
Bowman ED, Remaley AT, Forman MR, Skaug V, Zheng YL, Haugen A and
Harris CC: Serum estrogen and tumor-positive estrogen
receptor-alpha are strong prognostic classifiers of non-small-cell
lung cancer survival in both men and women. Carcinogenesis.
31:1778–1786. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu CT, Chang YL, Shih JY and Lee YC: The
significance of estrogen receptor beta in 301 surgically treated
non-small cell lung cancers. J Thorac Cardiovasc Surg. 130:979–986.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hammes SR and Levin ER: Extranuclear
steroid receptors: Nature and actions. Endocr Rev. 28:726–741.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fox EM, Andrade J and Shupnik MA: Novel
actions of eatrogen to promote proliferation: Intergration of
cytoplasmic and nuclear pathways. Steroids. 74:622–627. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fan S, Liao Y, Liu C, Huang Q, Liang H, Ai
B, Fu S and Zhou S: Estrogen promotes tumor metastasis via estrogen
receptor beta-mediated regulation of matrix-metalloproteinase-2 in
non-small cell lung cancer. Oncotarget. 8:56443–56459.
2017.PubMed/NCBI
|
|
41
|
Nose N, Uramoto H, Iwata T, Hanagiri T and
Yasumoto K: Expression of estrogen receptor beta predicts a
clinical response and longer progression-free survival after
treatment with EGFR-TKI for adenocarcinoma of the lung. Lung
Cancer. 71:350–355. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang Z, Li Z, Ding X, Shen Z, Liu Z, An T,
Duan J, Zhong J, Wu M, Zhao J, et al: ERβ localization influenced
outcomes of EGFR-TKI treatment in NSCLC patients with EGFR
mutations. Sci Rep. 5:113922015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fu S, Liu C, Huang Q, Fan S, Tang H, Fu X,
Ai B, Liao Y and Chu Q: Estrogen receptor β1 activation accelerates
resistance to epidermal growth factor receptor-tyrosine kinase
inhibitors in non-small cell lung cancer. Oncol Rep. 39:1313–1321.
2018.PubMed/NCBI
|
|
44
|
Zhang G, Yanamala N, Lathrop KL, Zhang L,
Klein-Seetharaman J and Srinivas H: Ligand-independent
antiapoptotic function of estrogen receptor-beta in lung cancer
cells. Mol Endocrinol. 24:1737–1747. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hershberger PA, Stabile LP, Kanterewicz B,
Rothstein ME, Gubish CT, Land S, Shuai Y, Siegfried JM and Nichols
M: Estrogen receptor beta (ERbeta) subtype-specific ligands
increase transcription, p44/p42 mitogen activated protein kinase
(MAPK) activation and growth in human non-small cell lung cancer
cells. J Steroid Biochem Mol Biol. 116:102–109. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Swedenborg E, Power KA, Cai W, Pongratz I
and Ruegg J: Regulation of estrogen receptor beta activity and
implications in health and disease. Cell Mol Life Sci.
66:3873–3894. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Levin ER: Bidirectional signaling between
the estrogen receptor and the epidermal growth factor receptor. Mol
Endocrinol. 17:309–317. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kato S, Endoh H, Masuhiro T, Kitamoto T,
Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H,
et al: Activation of the estrogen receptor through phosphorylation
by mitogen-activated protein kinase. Science. 270:1491–1494. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang G, Liu X, Farkas AM, Parwani AV,
Lathrop KL, Lenzner D, Land SR and Srinivas H: Estrogen receptor
beta functions through nongenomic mechanisms in lung cancer cells.
Mol Endocrinol. 23:146–156. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Traynor AM, Schiller JH, Stabile LP,
Kolesar JM, Eickhoff JC, Dacic S, Hoang T, Dubey S, Marcotte SM and
Siegfried JM: Pilot study of gefitinib and fulvestrant in the
treatment of post-menopausal women with advanced non-small cell
lung cancer. Lung Cancer. 64:51–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Garon EB, Siegfried JM, Dubinett SM,
Elashoff RM, Park DJ, Parikh RJ, Patel R, Hu EH, Reckamp KL, Adams
B, et al: Abstract 4664: Result of TORI L-03, a randomized,
multi-center phase II clinical trial of erlotinib (E) or E +
fulvestrant (F) in previously treated advanced non-small cell lung
cancer (NSCLC)AACR 104th Annual Meeting Washington DC. Philadelphia
(PA): AACR 73. Apr 6–10–2013
|
